GI Insights

With so many treatment options currently available for moderate to severe Crohn’s disease and ulcerative colitis, how do you know which one will work best for your patients? Joining Dr. Peter Buch to help answer that and other questions is Dr. Philip Ginsburg, Medical Director of Research and the Director of the Inflammatory Bowel Disease Center of Connecticut.

Tofacitinib is a common treatment option for patients with ulcerative colitis. But it’s not without its risks. Here to share what we need to consider before we start our patients on tofacitinib is Dr. Philip Ginsburg, Medical Director of Research and the Director of the Inflammatory Bowel Disease Center of Connecticut.

Treat-to-target is the current standard for the management of IBD, and as such it is imperative to understand what those targets are, what strategies will help you achieve them, and the importance of integrating a patient-focused therapeutic plan. Join Dr. Miguel Regueiro and Dr. Neil Nandi as they explore practical approaches to defining therapeutic success and provide listeners with solutions and recommendations to ultimately improve long-term IBD patient outcomes.

To view and download the Crohn's and Colitis Foundation's appeal letters referenced in this program, click here!

The treatment and evaluation of inflammatory bowel disease, or IBD, is continuously changing to provide the best quality of care for patients. Dr. Peter Buch is joined by Dr. Jeffrey Basile, a gastroenterologist from Charleston GI, to shed some light on the latest treatment options for IBD patients.

Now that we have therapies like vedolizumab and ustekinumab, many are wondering if there’s still a role for anti-TNFs in the treatment of IBD. Here to share his perspective and how he uses the multitude of available treatment options to his advantage is Dr. Jeffrey Basile, a gastroenterologist from Charleston GI.

Clostridium difficile impacts many patients around the United States. How can we better diagnose and treat this infection? Dr. Peter Buch is joined by Dr. Paul Feuerstadt, Assistant Clinical Professor of Medicine at Yale New Haven Hospital the discuss the importance of managing Clostridium difficile.

Irritable bowel syndrome can be difficult to manage for both physicians and patients. What can we do to help better diagnose and manage IBS? Here today is Dr. Neil Nandi who is discussing the IBS Guidelines highlights with Dr. Brain Lacy, a gastroenterologist at the Mayo Clinic, Jacksonville, Florida, and the co-editor-in-chief of the American Journal of Gastroenterology.

What do we need to know about choosing the right medication for our patients with IBS? Stay tuned as Dr. Neil Nandi talks with Dr. Brain Lacy, a gastroenterologist at the Mayo Clinic, Jacksonville, and the co-editor-in-chief of the American Journal of Gastroenterology, on these pharmacologic therapies.

Non-cardiac chest pain, NCCP, is chest pain in patients who do not have heart disease. How do we identify and diagnose NCCP? Stay tuned as Dr. Peter Buch talks with Dr. Ronnie Fass, Chief of the Division of Gastroenterology and Hepatology, on the important aspects of non-cardiac chest pain.

Patients with an inflammatory bowel disorder, or IBD, often suffer from post-traumatic stress disorder, or PTSD. But how do the psychological impacts of PTSD impact our IBD patients? Dr. Neil Nandi is joined by Dr. Tiffany Taft, the Director of Psychogastroenterology Research in the Division of Gastroenterology and Hepatology at Northwestern University, to discuss IBD’s relationship with PTSD.